| Patient | Joe Frazier |
|---|---|
| Date of birth | 1962-01-12 |
| Identifiers | MRN HR-BX004-SYN; SSN (made up) 000-04-5590 |
| Document date | 2026-03-02 |
| Author | Clarence Whitfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review of home blood pressure readings, with liver elastography, ultrasound and hepatology. [S]
Mr. Frazier returns two weeks after intake with a week of home blood pressure readings, twice a day, averaging 146/90. He is taking metformin, lisinopril and the new atorvastatin without trouble. This morning he had liver elastography and a liver ultrasound, and he saw Dr. Deshpande of hepatology. He has had no swelling of the legs or abdomen, no black stools, no confusion and no yellowing. He drinks one or two beers on some weekends and agreed today to stop. He asked what a scarred liver means for his work at the gym. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 146/90 over seven days |
| Atorvastatin | Two weeks; no muscle aches |
| Liver symptoms | None |
| Alcohol | Agreed to stop |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No abdominal swelling, black stools or vomiting of blood |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Neurological | Negative | No confusion or day-night reversal |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years | One tablet twice daily with meals | Oral route | 2026-02-16 | active | S |
| Lisinopril 20 mg oral tablet, one tablet daily; taken for years | One tablet daily | Oral route | 2026-02-16 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-16 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-04-13 | completed | S |
| Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly | 0.25 mg weekly for four weeks, then 0.5 mg weekly | Subcutaneous route | 2026-03-02 to 2026-05-18 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-02 | Body height | 182 | cm | S |
| 2026-03-02 | Body weight | 103.6 | kg | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 31.3 | kg/m2 | S |
| 2026-03-02 | Systolic blood pressure | 148 | mm[Hg] | S |
| 2026-03-02 | Diastolic blood pressure | 90 | mm[Hg] | S |
| 2026-03-02 | Heart rate | 74 | /min | S |
| 2026-03-02 | Respiratory rate | 16 | /min | S |
| 2026-03-02 | Body temperature | 36.6 | Cel | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-02 | Liver stiffness by US.transient elastography | 17.6 | kPa | Below 8 kPa makes advanced fibrosis unlikely; 15 kPa or higher is consistent with compensated advanced chronic liver disease | High | S |
| 2026-03-02 | INR in Platelet poor plasma by Coagulation assay | 1.1 | {INR} | 0.8-1.2 | Normal | S |
| 2026-03-02 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 4.2 | ng/mL | <=8.3 ng/mL | Normal | S |
Vital signs recorded on 2026-03-02; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 148/90, pulse 74; weight 103.6 kg |
| Abdomen | Soft; liver edge firm at the costal margin; spleen tip not felt; no ascites |
| Skin | No jaundice, spider angiomas or palmar erythema |
| Neurological | No asterixis |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetes | active | confirmed | E11.65 | S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic. |
| Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressure | active | confirmed | I10 | S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life. |
| Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluated | resolved | confirmed | R74.01 | S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis. |
| Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcohol | active | confirmed | K76.0 | S — Synthetic modern diagnosis. Not part of the public record of his life; chosen to teach surveillance. |
| Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh A | active | confirmed | K74.69 | S — Synthetic modern diagnosis. Not part of the public record of his life; the liver cancer diagnosed three years later in the true frame does not appear in the modern episode. |
| Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statin | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Obesity, class 1 (BMI 31.4) | active | confirmed | E66.811 | S — Synthetic finding; described without stigma. |
| Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30 | active | confirmed | H54.62 | S — Synthetic modern measurement anchored to the documented cataract in his left eye. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (clinic and home), weight and BMI | Every visit | Completed today | 148/90 in the clinic; home average 146/90; weight 103.6 kg |
| Laboratory | Hemoglobin A1c | Every 3 months until at goal or after a change in treatment, then every 6 months | Up to date | 8.4% two weeks ago; next in three months |
| Medication safety | Low blood sugar review and medicine tolerability | Every visit | Completed today | No low blood sugar; metformin tolerated |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin, then yearly | Up to date | Atorvastatin started two weeks ago; lipids at eight weeks |
| Laboratory | Potassium, creatinine and eGFR (CKD-EPI 2021) on lisinopril | Every 6 months on an ACE inhibitor, and after changes | Up to date | Potassium 4.6, creatinine 1.08 mg/dL, eGFR 77 two weeks ago |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Up to date | 18 mg/g two weeks ago |
| Laboratory | Liver tests with FIB-4 | Yearly with diabetes; FIB-4 1.3 or higher leads to elastography | Up to date | FIB-4 3.43 two weeks ago (age 64, AST 48, ALT 42, platelets 138): high risk |
| Imaging | Transient elastography | When FIB-4 is 1.3 or higher; repeat in 1 to 2 years | Completed today | Liver stiffness 17.6 kPa; controlled attenuation parameter 318 dB/m |
| Imaging | Liver ultrasound with AFP for hepatocellular carcinoma surveillance | Every 6 months in cirrhosis | Completed today | Baseline ultrasound without a focal lesion; AFP 4.2 ng/mL |
| Laboratory | Liver function (albumin, bilirubin, INR, platelets; Child-Pugh and MELD) | At diagnosis, then every 6 months | Completed today | INR 1.1, albumin 4.0, bilirubin 0.9, platelets 138; Child-Pugh A5, MELD 8 |
| Referral | Variceal screening | Endoscopy when portal hypertension cannot be ruled out; repeat in 2 years if no varices and the liver injury continues | Ordered | Upper endoscopy booked for next month |
| Self-management | Alcohol abstinence | Every visit | Completed today | Agreed to stop the occasional beer |
| Self-management | No NSAIDs; acetaminophen no more than 2 g a day | Every visit | Completed today | Explained; he uses no pain medicine now |
| Self-management | Vaccines for diabetes and chronic liver disease | At diagnosis of chronic liver disease | Completed today | PCV20 and first doses of hepatitis A and B vaccines today |
| Referral | Hepatology consultation | At diagnosis of advanced fibrosis or cirrhosis | Completed today | Seen by Dr. Deshpande today |
| Self-management | Medicine cost and coverage | With each new medicine | Completed today | Semaglutide approved after prior authorization; generics for the rest |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20; Hepatitis B vaccine (HepB-CpG), dose 1 of 2; Hepatitis A vaccine, adult, dose 1 of 2 [S]
Guideline basis: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); Baveno VII - Renewing consensus in portal hypertension (2022); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026)
Follow-up: Endoscopy next month. Visit in six weeks with lipids, potassium, creatinine and home readings. Diabetes class. Next scheduled visit 2026-04-13: eight-week review: blood pressure, lipids, kidney function, semaglutide, the endoscopy result and vaccines. [S]